Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 5;15(8):e42995.
doi: 10.7759/cureus.42995. eCollection 2023 Aug.

Crohn's Disease is a Greater Risk Factor for Nonalcoholic Fatty Liver Disease Compared to Ulcerative Colitis: A Systematic Review

Athri Kodali  1 , Chiugo Okoye  1 , Dhadon Klein  2 , Iman Mohamoud  1 , Olawale O Olanisa  1 , Panah Parab  1 , Priti Chaudhary  1 , Sonia Mukhtar  3   4 , Ali Moradi  5   1 , Pousette Hamid  6
Affiliations
Review

Crohn's Disease is a Greater Risk Factor for Nonalcoholic Fatty Liver Disease Compared to Ulcerative Colitis: A Systematic Review

Athri Kodali et al. Cureus. .

Abstract

Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases that have been associated with nonalcoholic fatty liver disease (NAFLD). This systematic review aimed to examine whether Crohn's disease confers a greater risk for nonalcoholic fatty liver disease compared to ulcerative colitis. A comprehensive search of electronic databases from January 2000 to May 2023 was conducted to identify observational studies investigating the association between Crohn's disease or ulcerative colitis and nonalcoholic fatty liver disease. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 checklist ensured transparent reporting, and the Newcastle-Ottawa Scale was used to assess study quality. Data synthesis revealed higher nonalcoholic fatty liver disease prevalence among Crohn's disease patients compared to ulcerative colitis patients across regions. Ten studies published between 2016 and 2022, encompassing a total of 4164 participants from three continents, were included in the review. The median proportion of Crohn's disease patients with nonalcoholic fatty liver disease was 37.22% (range: 10.95-53.80%), while it was 27.55% (range: 8.60-46.20%) for ulcerative colitis patients. Subgroup analysis by region confirmed CD's higher NAFLD risk. Median proportions for CD patients who developed NAFLD from North America, Europe, and Asia were 25.97% (range: 14.6-37.33%), 47.01% (range: 14.2-53.8%), and 20.78% (range: 10.95-30.6%), respectively, and the median proportion of persons with UC who developed NAFLD in studies from North America, Europe, and Asia were 17.28% (range: 8.6-25.96%), 37.70% (range: 25.64-46.20%), and 19.52% (range: 10.14-28.90%), respectively. Variations suggest differing mechanisms, disease features, and therapeutics. Transmural inflammation in Crohn's disease may increase metabolic abnormalities, including nonalcoholic fatty liver disease. Geographic differences in lifestyle, genetics, and environmental variables may also contribute. This review demonstrates that Crohn's disease patients face a higher nonalcoholic fatty liver disease risk than ulcerative colitis patients, emphasizing the need for early monitoring and prevention. Further studies are warranted to understand mechanisms and develop tailored management approaches.

Keywords: (ibd) inflammatory bowel disease; crohn’s disease (cd); nafld; nonalcoholic fatty liver disease (nafld); nonalcoholic steatohepatitis; risk factors for nonalcoholic fatty liver disease; ulcerative colitis (uc).

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. PRISMA statement diagram delineating the process by which articles were screened and ultimately included
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Figure 2
Figure 2. Region-wise distribution of number of study participants.
The image is created by the authors of this study.
Figure 3
Figure 3. Comparison of NAFLD prevalence in CD patients versus UC patients by country and region.
NAFLD: nonalcoholic fatty liver disease; CD: Crohn's disease; UC: ulcerative colitis The image is created by the authors of this study.
See this image and copyright information in PMC

References

    1. Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century. Ananthakrishnan AN, Kaplan GG, Ng SC. Clin Gastroenterol Hepatol. 2020;18:1252–1260. - PubMed
    1. Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. Sartini A, Gitto S, Bianchini M, et al. Cell Death Dis. 2018;9 - PMC - PubMed
    1. Non-alcoholic fatty liver disease. Powell EE, Wong VW, Rinella M. Lancet. 2021;397:2212–2224. - PubMed
    1. Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease. Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Inflamm Bowel Dis. 2016;22:1937–1944. - PubMed
    1. Nonalcoholic fatty liver disease is common in IBD patients however progression to hepatic fibrosis by noninvasive markers is rare. Ritaccio G, Stoleru G, Abutaleb A, Cross RK, Shetty K, Sakiani S, Wong U. Dig Dis Sci. 2021;66:3186–3191. - PMC - PubMed

LinkOut - more resources